Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric and adult patients. It has a longer half-life compared to other benzodiazepines.
## Primary Indications
Adjunctive therapy for seizures in Lennox-Gastaut Syndrome (LGS).
## Adult Dosing
* **Initial:** 5 mg twice daily.
* **Titration:** Increase dose every 2 weeks by 5 mg to 10 mg twice daily, based on clinical response and tolerability.
* **Usual Maintenance:** 10 mg to 20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (LGS)
* **2 to <10 years:**
* **Initial:** 2.5 mg twice daily.
* **Titration:** Increase dose every 2 weeks by 2.5 mg to 5 mg twice daily, based on clinical response and tolerability.
* **Usual Maintenance:** 5 mg twice daily.
* **Maximum:** 10 mg twice daily (20 mg/day).
* **≥10 years (or weight ≥30 kg):**
* **Initial:** 5 mg twice daily.
* **Titration:** Increase dose every 2 weeks by 5 mg to 10 mg twice daily, based on clinical response and tolerability.
* **Usual Maintenance:** 10 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; no specific dose adjustment is recommended, but initiation at the lower end of the dosing range and slow titration may be appropriate.
* **Renal Impairment:** Use with caution; no specific dose adjustment is recommended, but initiation at the lower end of the dosing range and slow titration may be appropriate.
## Contraindications
* Hypersensitivity to clobazam or any component of the formulation.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, drowsiness, constipation, decreased appetite, aggression, irritability, fatigue, ataxia, drooling.
* **Serious:** Suicidal ideation and behavior, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, cognitive impairment.
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other benzodiazepines, sedatives/hypnotics):** Additive CNS depression; increased risk of sedation, respiratory depression, and death. Use concomitantly with extreme caution.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam concentrations.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, protease inhibitors):** May increase clobazam concentrations.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam concentrations.
* **Other Anticonvulsants:** Monitor for increased CNS depression or paradoxical reactions.
## Monitoring
* **Clinical:** Assess for seizure frequency and severity, and signs/symptoms of LGS.
* **Adverse Effects:** Monitor for somnolence, dizziness, coordination difficulties, and any signs of serious reactions (e.g., suicidal thoughts, severe rash).
* **Behavioral:** Observe for changes in mood, behavior, or cognition, especially in children.
* **Withdrawal Symptoms:** Monitor for signs of withdrawal if discontinuing the medication abruptly.
## Clinical Pearls
* Clobazam is intended for adjunctive use in LGS; it is not a first-line monotherapy.
* Due to its long half-life, accumulation can occur, especially with higher doses or in patients with impaired hepatic/renal function.
* Tapering of the dose is recommended upon discontinuation to avoid withdrawal symptoms.
* The risk of suicidal ideation and behavior is present with all antiepileptic drugs; patients should be monitored closely.
* Dose titration should be slow and individualized.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace professional medical advice. Always consult the most current prescribing information and guidelines for the specific product and patient.
